The significance of the result lies in what it replaces. Conventional COF synthesis typically demands days of heating under aggressive acid- or base-catalysed conditions, extensive screening of solvents and temperatures, and careful matching of reaction conditions to each monomer combination. Even then, many products emerge with imperfect crystallinity or compromised porosity, the two properties that make COFs valuable for gas separation, catalysis, energy storage and proton conduction. The new strategy, by contrast, produces imide-, imine-, hydrazone- and sp2-carbon-linked COFs within hours, with high crystallinity and porosity, using a catalyst that can be recovered and used again.

Benzimidazole occupies a special position among organic molecules because it is amphiprotic: it can donate a hydrogen bond through its N-H group and accept one through its pyridine-like nitrogen. That dual character is the engine of the new method. Unlike conventional acid or base catalysis, which activates monomers by proton transfer, the benzimidazole catalysts engage monomers, intermediates and transition states simultaneously through explicit hydrogen-bonding interactions, lowering the energy barrier at every step of the polymerization rather than at just one.

The authors demonstrate the approach most thoroughly on imide-linked COFs, a class prized for its chemical robustness and its applications in batteries, sensing and carbon capture. In the prototypical TAPB-PMDA-COF, formed from a triamine and a dianhydride, the catalyst accelerates the imidization reaction while promoting its reversibility, so that the growing network can continuously repair defects and settle into the thermodynamically favoured crystalline state. Powder X-ray diffraction profiles of the resulting materials show sharp reflections and narrow full widths at half maximum, hallmarks of long-range order that typically require days of solvothermal treatment to achieve.

Control is a second virtue of the method. Because the catalyst acts through noncovalent interactions rather than stoichiometric consumption, the reaction outcome can be tuned simply by varying the catalyst-to-monomer ratio. This knob allows the team to balance reaction rate against error correction: too little catalyst leaves the system slow and kinetically trapped, while the right proportion drives rapid bond formation and rapid bond exchange in parallel, the combination that crystalline polymer growth requires. The same logic extends across linkage chemistries, as the team showed by preparing the imine-linked TPB-DMTP-COF, the hydrazone-linked COF-43 and the sp2-carbon-conjugated sp2c-COF-16 under the same catalytic regime.

Theoretical calculations by Hongde Yu and Thomas Heine at the Technical University of Dresden, performed with density functional theory, support this mechanistic picture. The computations indicate that hydrogen-bonding interactions with the catalyst stabilize the transition states of the linkage-forming reactions and lower activation barriers for both the forward and reverse directions. Reversibility is the crucial ingredient: a network that can break and remake its bonds while it forms is one that can anneal itself into crystallinity, whereas an irreversible polymerization locks in disorder.

Scalability has long been the Achilles heel of COF chemistry, because many celebrated syntheses yield only tens or hundreds of milligrams after days of reaction. The hydrogen-bonding protocol supports a 1,000-fold scale-up, and the catalyst itself can be reused, addressing both the cost and the waste streams that would otherwise accompany industrial production. The scaled materials retain the high crystallinity and porosity of their small-batch counterparts, suggesting that the catalytic mechanism is robust to the heat- and mass-transfer realities of larger reactors.

The practical payoff is illustrated by proton conduction, a property central to fuel cells and electrolyzers. COFs prepared by the new route achieve benchmark proton conductivity, consistent with the team’s earlier work showing that crystalline porous frameworks can serve as exceptional proton-conducting electrolytes when their pores are engineered with appropriate carrier chemistry. Because the hydrogen-bonding synthesis delivers frameworks with well-defined channels and high surface areas, the resulting membranes combine the structural order needed for efficient transport with the mechanical and chemical stability demanded by devices.

The strategy also draws on a distinguished lineage in organic chemistry. Explicit hydrogen-bonding organocatalysis, pioneered for enantioselective reactions by chemists such as Peter Schreiner and Eric Jacobsen, relies on small-molecule donors that activate substrates without transferring protons. Applying that philosophy to polymer crystallization is conceptually elegant: the same interactions that guide a single reaction’s transition state can, when applied throughout a growing network, guide the entire system toward order. The result is a synthesis that is simultaneously faster, milder and more general than the harsh protocols it replaces.

For a field whose promise has often outrun its practicality, the message is striking. A cheap, recyclable heterocycle, acting through nothing more exotic than hydrogen bonds, can now build some of the most sophisticated materials in chemistry in hours instead of days, at gram scale instead of milligram scale, and with the crystalline quality that applications demand. If the approach proves as general across monomer families as the initial results suggest, hydrogen-bonding catalysis may become the default route to covalent organic frameworks, and the porous architectures built from it may finally move from the pages of review articles into the membranes, electrodes and catalysts of working technology.

Subject of Research: Hydrogen-bonding organocatalysis for the rapid, scalable synthesis of crystalline covalent organic frameworks

Article Title: Synthesis of covalent organic frameworks through hydrogen-bonding catalysis

Article References: Ye, X., Tao, S., Yu, H., Heine, T., Shao, H., Mu, X., Liu, Y., Xu, H., Lin, M., & Jiang, D. (2026). Synthesis of covalent organic frameworks through hydrogen-bonding catalysis. Nature Synthesis. https://doi.org/10.1038/s44160-026-01180-8

Image Credits: AI Generated

DOI: 10.1038/s44160-026-01180-8

Keywords: covalent organic frameworks, hydrogen-bonding catalysis, benzimidazole, organocatalysis, porous materials, imide-linked COFs, crystallinity, proton conduction, polymer synthesis, Nature Synthesis, scale-up, reversible polymerization

The molecule, named N1,N4-bis((1H-benzo[d]imidazol-2-yl)methyl)cyclohexane-1,4-dicarboxamide, or BCHDA, was assembled by coupling 2-aminomethylbenzimidazole with cyclohexane-1,4-dicarboxylic acid in pyridine, using triphenyl phosphite as a dehydrating agent. The reaction produced a white solid in 44 percent yield with a melting point of 310 degrees Celsius. Its structure was confirmed through elemental analysis, FT-IR and UV-visible spectroscopy, proton and carbon-13 NMR, high-resolution mass spectrometry and single-crystal X-ray diffraction. The proton NMR revealed a roughly 7:1 mixture of cis and trans isomers around the central cyclohexane ring, a detail the team tracked carefully through the characteristic resonances of the axial and equatorial hydrogens.

What makes BCHDA special is its architecture. Where most previously studied benzimidazole inhibitors carry a single fused aromatic ring, BCHDA carries two, linked through amide bridges to a cyclohexane core. Each benzimidazole unit is rich in electron-donating nitrogen atoms, and the amide groups add further oxygen and nitrogen donor sites. In principle, this gives the molecule multiple anchoring points for bonding to an iron surface, along with an extended conjugated pi-electron system capable of sharing electron density with vacant metal d-orbitals. The researchers set out to test whether this dual-ring design translates into superior protection.

The electrochemical evidence was unambiguous. Using potentiodynamic polarization in 0.5 molar sulfuric acid, the team found that adding BCHDA suppressed both the anodic dissolution of iron and the cathodic evolution of hydrogen gas. The corrosion potential shifted by less than 85 millivolts relative to the blank solution, the accepted signature of a mixed-type inhibitor acting on both halves of the corrosion reaction. At the highest concentration tested, 10 to the minus 3 molar, and at 298 kelvin, the corrosion current density fell so dramatically that the calculated inhibition efficiency reached 99.13 percent. Efficiency rose with concentration but declined with temperature, dropping to 92.80 percent at 328 kelvin at the same dose, a pattern consistent with partial desorption of the inhibitor film as thermal agitation increases.

Electrochemical impedance spectroscopy told a matching story. The Nyquist plots showed depressed capacitive semicircles whose diameters grew steadily with inhibitor concentration, reflecting a rising charge-transfer resistance at the metal-electrolyte interface. The data fitted well to a two-time-constant equivalent circuit, with one relaxation process assigned to the dielectric response of the adsorbed inhibitor film and the other to charge transfer across the double layer. From the impedance measurements the team derived a maximum inhibition efficiency of 94.32 percent at 10 to the minus 3 molar and 298 kelvin. The small discrepancy with the Tafel-derived figure arises because the two techniques probe different aspects of the corrosion process, one under finite overpotential and the other near open circuit, yet both showed the same concentration-dependent trend.

Adsorption analysis showed that the surface coverage data followed the Langmuir isotherm almost perfectly, indicating monolayer adsorption on energetically equivalent sites with negligible interaction between adsorbed molecules. The standard free energy of adsorption came out near minus 40 kilojoules per mole, right at the boundary between physical and chemical adsorption, while the adsorption enthalpy of minus 72.23 kilojoules per mole pointed clearly toward dominant chemisorption. The negative adsorption entropy indicated that the molecules become more ordered as they assemble into a protective layer at the metal-solution interface. Arrhenius analysis added further support, with activation energies for the inhibited systems exceeding those of the blank acid, confirming that the adsorbed film acts as a genuine kinetic barrier.

Direct imaging sealed the case. Scanning electron micrographs of polished steel showed a smooth surface marked only by polishing lines. After 24 hours in uninhibited sulfuric acid the surface was ravaged by cracks, pits and irregular corrosion products. In acid containing BCHDA the damage was dramatically reduced, with the 10 to the minus 3 molar sample retaining the smoothest morphology. Energy-dispersive X-ray analysis quantified the difference: iron content on the surface fell from 98.73 percent on polished steel to 56.35 percent after uninhibited acid exposure, but recovered to 71.52 percent in the presence of the inhibitor, while oxygen from oxide corrosion products dropped from nearly 40 percent to about 13 percent. Crucially, carbon and nitrogen signals appeared on the protected surfaces, direct fingerprints of adsorbed BCHDA molecules.

To understand why the molecule works so well, the team turned to density functional theory at the B3LYP/6-311+G(d,p) level, computing descriptors for both the neutral molecule and its protonated form, which predominates in sulfuric acid. The neutral species showed a HOMO energy of minus 6.09 electron-volts, a small frontier orbital gap of 1.74 electron-volts and a high electrophilicity index, all markers of a molecule well suited to donating and accepting electron density at a metal surface. Protonation widened the gap to 3.06 electron-volts and reduced the electron-donating capacity, yet the protonated form remained strongly surface-active. Natural bond orbital analysis revealed powerful intramolecular charge-transfer interactions, including a sigma-to-lone-pair stabilization of 43.04 kilocalories per mole in the neutral molecule and a pi-to-pi-star delocalization of 45.23 kilocalories per mole in the protonated species, confirming that the conjugated framework stays electronically robust under acidic conditions.

Molecular dynamics simulations on a four-layer iron (110) slab in aqueous sulfuric acid provided the final molecular-scale picture. The neutral BCHDA molecule bound to the surface with an interaction energy of minus 185 kilocalories per mole, lying nearly parallel to the metal to maximize contact between its pi-system and the iron atoms. The protonated form, though slightly weaker at minus 160 kilocalories per mole, still adsorbed spontaneously through a synergistic combination of electrostatic attraction to the sulfate-charged surface and residual donor-acceptor bonding through unprotonated nitrogen sites. Together, the experiments and simulations reveal a dual-mode mechanism: rapid electrostatic coverage by protonated molecules followed by durable chemisorption of neutral ones through nitrogen and oxygen lone pairs and aromatic pi-electrons. The authors argue that this integrated experimental-theoretical strategy offers a blueprint for rationally designing the next generation of corrosion inhibitors, positioning bis-benzimidazole derivatives as promising candidates for protecting steel in some of the harshest acidic environments industry can produce.

Subject of Research: Corrosion inhibition of mild steel in sulfuric acid by a bis-benzimidazole diamide derivative

Article Title: Experimental and computational studies on the corrosion inhibition of Bisbenzimidazole diamide derivative on mild steel in acidic media

Article References: Kumar, A., Jain, R., Kumar, S., Sanyukta, Shabnam, Vashisht, H., Baxi, S., Mahiya, K., Mathias, G. E., Anadebe, V. C., Olasunkanmi, L. O., & Ebenso, E. E. (2026). Experimental and computational studies on the corrosion inhibition of Bisbenzimidazole diamide derivative on mild steel in acidic media. Discover Electrochemistry, 3(1), Article 86. https://doi.org/10.1007/s44373-026-00175-6

Image Credits: AI Generated

DOI: 10.1007/s44373-026-00175-6

Keywords: corrosion inhibition, mild steel, benzimidazole, sulfuric acid, electrochemical impedance spectroscopy, potentiodynamic polarization, density functional theory, molecular dynamics, Langmuir isotherm, chemisorption, SEM-EDX, protective film

The therapeutic logic behind the work rests on the deep biological overlap between inflammatory and allergic disease. COX-2 catalyzes the conversion of arachidonic acid into prostaglandins when tissues become inflamed, driving pain, fever, and swelling, while histamine acting through H1 receptors triggers vasodilation, smooth muscle contraction, and itching. In conditions such as allergic rhinitis with sinus inflammation or chronic urticaria with an inflammatory component, both pathways fire at once. A compound that engages both could, in principle, deliver synergistic benefit, lower the effective dose of each mechanism, reduce drug-drug interactions, and improve patient adherence. The authors point to rupatadine, which combines H1 antagonism with platelet-activating factor inhibition, as an existing proof that multi-target antihistamines can succeed clinically.

The benzimidazole scaffold was a deliberate choice. This fused benzene-imidazole ring system structurally resembles the purine bases of DNA, which helps it form favorable contacts with a wide range of biological targets. Benzimidazole drugs already span an impressive pharmacological range, from anti-inflammatory and antimicrobial to antiviral, anticancer, and antiparasitic activity. Previous studies have shown that suitably substituted benzimidazoles can act as selective COX-2 inhibitors with improved gastrointestinal safety compared with traditional NSAIDs; one reported series of methyl sulfonyl-substituted analogues achieved sub-micromolar inhibitory potency in enzyme assays. What had not been done before, according to the authors, was a systematic dual-target evaluation of a single benzimidazole series against both COX-2 and the H1 receptor.

The design itself was methodical. All eleven compounds, labeled SP1 through SP11, share a 2-phenyl-1H-benzimidazole core connected through an acetamide linker at the N-1 position to a variable substituent. That substituent was varied deliberately across chemical space: aromatic groups such as aniline and resorcinol, aldehyde-bearing moieties including salicylaldehyde and isovanillin, carboxylic acids ranging from formic to benzoic, chloroacetic, and salicylic acid, and simple aliphatic propanol and butanol chains. Each variation tunes lipophilicity, hydrogen-bonding capacity, and steric profile in a different way, allowing the team to read out structure-activity relationships directly from the docking results.

Before any docking was attempted, the compounds had to pass basic drug-likeness filters. Using the SwissADME web platform, the researchers confirmed that every derivative satisfied Lipinski’s Rule of Five and Veber’s oral bioavailability criteria without a single violation. Molecular weights ranged from 279.29 to 385.42 daltons, comfortably below the 500-dalton ceiling, while calculated LogP values between 1.02 and 3.72 suggested a workable balance between membrane permeability and aqueous solubility. Topological polar surface area values of 46.92 to 84.22 square angstroms and rotatable bond counts of five to seven fell within Veber’s limits, predicting efficient passive diffusion across the gut wall. In short, all eleven molecules looked like plausible oral drugs on paper.

Safety screening came next, using ProTox-III, a machine-learning platform trained on curated toxicological datasets. Predicted acute oral LD50 values ranged from 500 to 2000 milligrams per kilogram, placing every compound in GHS Toxicity Class IV, a category comparable to many approved pharmaceuticals. Human intestinal absorption was predicted to exceed 80 percent for the entire series, and carcinogenicity and mutagenicity predictions were negative for nearly all derivatives. Notably, low predicted blood-brain barrier penetration for most compounds hints at a peripherally acting antihistamine with reduced sedation risk, the defining drawback of first-generation H1 antagonists. One caution did emerge: SP7 and SP8 showed moderate predicted cardiotoxicity, a signal the authors stress must be verified with hERG channel assays, since cardiac liability contributed to the market withdrawal of some earlier COX-2 inhibitors.

The docking results were where the study delivered its headline findings. Using Schrödinger’s Glide Extra Precision protocol against human COX-2, the crystal structure of which was solved bound to ibuprofen, the team found that SP2, a resorcinol derivative, scored minus 8.032 kilocalories per mole and SP8, a salicylic acid derivative, scored minus 9.566 kilocalories per mole, both far ahead of ibuprofen’s benchmark of minus 5.779. The protocol was validated by re-docking the co-crystallized ligands, yielding root-mean-square deviations of 1.83 and 1.78 angstroms for COX-2 and the H1 receptor respectively, both under the accepted 2.0-angstrom threshold. SP8’s strength appears to come from its ortho-hydroxyl and carboxylate groups working in concert: the carboxylate forms a salt bridge with Arg120 while hydrogen bonds anchor to Tyr355 and Ser530, and hydrophobic packing into the enzyme’s channel stabilizes the complex.

Against the histamine H1 receptor, solved by cryo-electron microscopy in complex with desloratadine, the top performers were SP2 at minus 8.021 and SP11, a butanol-bearing derivative, at minus 8.627 kilocalories per mole, both surpassing the reference antihistamine astemizole at minus 6.519. These compounds engage the orthosteric binding pocket through hydrogen bonds with Asp107, Tyr108, Ser111, and Asn198, complemented by aromatic stacking against Trp428, Tyr431, and Phe432. The extended butyl chain of SP11 appears to fill hydrophobic sub-pockets lined by Phe432, Phe435, and Trp428, consistent with established structure-activity rules for lipophilic H1 ligands. Intriguingly, the SAR analysis suggested that lengthening the alkyl chain preferentially boosts H1 affinity over COX-2 affinity, giving medicinal chemists a tunable dial for target balance.

When docking affinity, drug-likeness, and predicted safety were weighed together, three compounds rose to the top for different reasons. SP2 shows the most balanced dual-target engagement, with its COX-2 and H1 docking scores within 0.1 kilocalories per mole of each other. SP8 is the strongest single COX-2 binder of the series, and SP11 the strongest H1 binder. A fourth compound, SP9, showed promising H1-selective trends thanks to a methoxy group that occupies a hydrophobic sub-pocket absent from COX-2, but its overall dual-target and safety profile did not outperform the three leads, so it was not carried forward. The authors are careful to note that GlideScores are empirical rankings, not thermodynamic binding free energies, and cannot substitute for measured inhibition constants.

That caveat frames the study’s honest limitations. Static docking cannot capture protein flexibility or induced-fit effects, and machine-learning ADMET models can be unreliable for chemotypes poorly represented in their training data. The authors recommend a clear experimental roadmap: synthesize SP2, SP8, and SP11; run in vitro COX-2 inhibition and H1 receptor binding assays; establish COX-1/COX-2 selectivity to gauge gastrointestinal risk; complete full experimental ADMET profiling including hERG testing; and then move to in vivo efficacy studies in inflammation and anaphylaxis models, with molecular dynamics simulations guiding further optimization. Until those experiments are done, the dual-acting promise of these molecules remains a well-supported hypothesis rather than a demonstrated therapy. Still, as a rational, hypothesis-generating screen, the work offers a concrete starting point for a next generation of medicines aimed at the frequent clinical overlap between allergy and inflammation.

Subject of Research: Computational evaluation of novel benzimidazole derivatives as dual COX-2 inhibitors and histamine H1 receptor antagonists

Article Title: Integrated computational evaluation of novel benzimidazole scaffolds as dual COX-2 inhibitory and histamine H1 antagonistic activity

Article References: Pawar, S., & Panzade, P. (2026). Integrated computational evaluation of novel benzimidazole scaffolds as dual COX-2 inhibitory and histamine H1 antagonistic activity. Discover Chemistry, 3(1), Article 566. https://doi.org/10.1007/s44371-026-01024-6

Image Credits: AI Generated

DOI: 10.1007/s44371-026-01024-6

Keywords: benzimidazole, COX-2 inhibition, histamine H1 receptor, molecular docking, drug-likeness, ADMET prediction, SwissADME, ProTox-III, Glide XP docking, structure-activity relationship, computer-aided drug design, dual-target therapeutics

The research focused on a population of domestic dogs from an endemic rural area, sampling between July and October 2025. Twenty naturally Uncinaria-infected dogs and two puppies were enrolled, alongside three uninfected dogs that served as comparators. Fecal and blood samples were collected repeatedly, with egg shedding quantified on days minus 14, minus 7, and day 0 using the Mini-FLOTAC technique, a flotation-based counting method prized for its accuracy in quantifying parasite eggs per gram of feces. At day 0, the dogs were treated with one of three common anthelmintics: fenbendazole, moxidectin, or milbemycin oxime. Efficacy was then measured with the fecal egg count reduction test, or FECRT, the gold-standard field method that compares egg counts before and after treatment, in this case at day 14 post-treatment.

One of the most striking findings concerns the sheer volatility of egg shedding before any drug was administered. Egg counts ranged from zero to 3,105 eggs per gram across the pre-treatment sampling window, with sharp swings between consecutive sampling days. The mean egg count rose from 122 eggs per gram at day minus 14 to 647.2 at day minus 7, only to fall back to 162.2 at day 0. Such dramatic fluctuation within a matter of days carries a sober practical message: a single fecal sample can badly misrepresent the true infection status of a dog. A negative or low count on one day might mask a substantial infection that would be revealed a week later, which is precisely why the authors argue for multi-sample fecal diagnostics in both clinical practice and surveillance programs.

When it came to treatment, the results split cleanly. Fenbendazole, a member of the benzimidazole class that disrupts the parasite’s microtubule machinery by binding to β-tubulin, achieved a 100 percent fecal egg count reduction. Moxidectin, a milbemycin-class macrocyclic lactone that interferes with glutamate-gated chloride channels in the worm’s nervous system, came close behind at 99.3 percent efficacy. Milbemycin oxime, however, managed only 76.8 percent reduction, a figure that falls short of the thresholds typically used to declare acceptable efficacy and that raises questions about how this drug performs against U. stenocephala under field conditions. Importantly, the researchers did not stop at counting eggs; they probed the molecular and phenotypic basis of drug susceptibility.

To assess benzimidazole resistance, the team performed an in vitro egg hatch assay, exposing hookworm eggs to increasing concentrations of a benzimidazole and measuring the concentration that inhibits hatching in half of the eggs, the IC50. Two IC50 values were recorded, 0.03 with a 95 percent confidence interval of 0.03 to 0.04, and 0.09 with a confidence interval of 0.08 to 0.10, both consistent with phenotypic susceptibility to the drug class. In other words, despite the modest performance of milbemycin oxime in the live animals, the benzimidazole pathway itself showed no functional signs of resistance in this population.

Molecular screening reinforced that conclusion. Using amplicon deep sequencing of the internal transcribed spacer 2 region of the ribosomal RNA gene, the researchers confirmed that U. stenocephala was the sole hookworm species present in the samples, ruling out hidden co-infections with other hookworms such as Ancylostoma species that could confound efficacy calculations. They then sequenced the β-tubulin isotype-1 gene, the canonical molecular target whose mutations are the best-validated markers of benzimidazole resistance in parasitic nematodes. Across codons 134, 167, 198, and 200, the positions most frequently implicated in resistance, no canonical resistance-associated single nucleotide polymorphisms were detected, either before or after treatment. The genetic evidence and the phenotypic egg hatch data thus tell a consistent story: this southern Italian population of U. stenocephala remains fully susceptible to benzimidazoles.

The clinical pathology component of the study adds a reassuring but nuanced dimension. Hematological and biochemical values in the infected dogs were mostly within reference limits, a profile consistent with low-intensity parasitism rather than clinically significant disease. The most frequent abnormalities were mild eosinophilia, the elevated eosinophil count typical of the immune response to helminths; slight hypoalbuminemia, a modest drop in the blood protein albumin that hookworms can induce through intestinal blood loss and protein leakage; and increased β-globulin fractions, reflecting the antibody-driven immune activation that chronic parasitic exposure produces. None of these findings amounted to the severe anemia or profound protein loss that can accompany heavy hookworm burdens, suggesting that in these naturally exposed dogs, U. stenocephala was more of a subclinical passenger than a dangerous pathogen.

That subclinical profile is itself part of the reason the parasite has flown under the radar. U. stenocephala, sometimes called the northern hookworm, is better adapted to cooler climates than its tropical and subtropical relatives, and its infections tend to produce lower egg outputs and milder clinical signs. Yet the parasite is being reported with increasing frequency in Europe, and without baseline data on its shedding dynamics, drug susceptibility, and clinical impact, veterinarians have had little ground to stand on when interpreting diagnostic results or choosing treatments. This study supplies exactly that baseline, and its message about the unreliability of single-sample diagnosis is likely to resonate well beyond the study region.

The work also carries broader significance for the global problem of anthelmintic resistance. In canine hookworms, particularly Ancylostoma caninum in North America, widespread resistance to multiple drug classes has become a serious clinical challenge, making the search for populations where susceptibility persists all the more valuable. By documenting, with molecular and phenotypic rigor, a European U. stenocephala population that still responds fully to fenbendazole and moxidectin, the researchers have established a reference point against which future changes can be measured. Continued surveillance of anthelmintic efficacy, they emphasize, is essential, because resistance mutations can spread rapidly once they arise, and the modest efficacy of milbemycin oxime observed here warrants closer attention in future studies.

For dog owners and veterinarians, the practical takeaways are concrete. Repeated fecal examinations over consecutive weeks give a far more accurate picture of hookworm infection than a single test, given the day-to-day variability in egg shedding documented here. Fenbendazole and moxidectin remain dependable choices against U. stenocephala in this region, while milbemycin oxime’s performance suggests it should not be assumed fully effective without verification. And as this underestimated hookworm continues its apparent expansion across Europe, the integrated approach demonstrated in Basilicata, pairing egg counts with clinical chemistry, deep amplicon sequencing, and egg hatch assays, offers a template for monitoring not just this species, but the wider and shifting landscape of canine parasitism in a changing world.

Subject of Research: Anthelmintic susceptibility and clinical impact of the canine hookworm Uncinaria stenocephala in naturally infected dogs

Article Title: Clinical pathology, parasitological evaluation, and anthelmintic resistance assessment in dogs naturally infected with Uncinaria stenocephala

Article References: Fagundes-Moreira, R., Bezerra-Santos, M. A., Šlapeta, J., & Otranto, D. (2026). Clinical pathology, parasitological evaluation, and anthelmintic resistance assessment in dogs naturally infected with Uncinaria stenocephala. Parasites & Vectors. https://doi.org/10.1186/s13071-026-07688-4

Image Credits: AI Generated

DOI: 10.1186/s13071-026-07688-4

Keywords: Uncinaria stenocephala, hookworms, dogs, anthelmintic resistance, benzimidazole, fenbendazole, moxidectin, milbemycin oxime, fecal egg count reduction test, egg hatch assay, β-tubulin, Parasites & Vectors